Lancet Rheumato:风湿病患者感染新冠病毒后的预后及相关因素

2020-06-19 医刀 MedSci原创

据报道,在意大利,北部地区的伦巴第大区(Lombardy)发生的COVID-19病例数最多。其中,风湿性和肌肉骨骼疾病患者感染COVID-19的发生率相对较高。本研究目的是分析居住在伦巴第大区的风湿和

据报道,在意大利,北部地区的伦巴第大区(Lombardy)发生的COVID-19病例数最多。其中,风湿性和肌肉骨骼疾病患者感染COVID-19的发生率相对较高。本研究目的是分析居住在伦巴第大区的风湿和肌肉骨骼疾病患者的发生重度急性呼吸系统综合症冠状病毒2(SARS-CoV-2)感染的过程。

这是一个单中心的观察性研究,收集在门诊就诊的风湿性和肌肉骨骼疾病患者的数据,以鉴定SARS-CoV-2的感染或疑似感染的病例。此外,还对所有确诊为COVID-19肺炎的风湿性和骨骼肌肉疾病患者进行了病例对照研究。

2020年2月24日-2020年5月1日,共收集了1525位风湿和肌肉骨骼疾病患者的数据:其中118位(8%)患者出现COVID-19感染的症状。65位患者进行了咽拭子检测证实SARS-CoV-2感染,52位患者有一系列症状但未进行咽拭子检测。确诊COVID-19的患者比疑似患者的年龄更大(中位年龄:68 vs 57岁;p=0.001),也更容易出现动脉高血压(52% vs27%;OR 2.8,95% CI 1.3-6.1;p=0.031)和肥胖(17% vs 2%;OR 11.0,1.3-83.4;p=0.0059)。确诊和疑似病例在风湿病或背景治疗方面均无差异。65例确诊为COVID-19感染的患者中有47例(72%)发展成肺炎,需要入院治疗。在这117位确诊或疑似COVID-19感染的患者中,12人(10%)死亡(10例确诊,2例疑似)。死亡的确诊患者比幸存的患者年龄大(78.8 vs 65.5岁,p=0.0002)。此外,在性别、合并症或治疗方面,死亡和幸存患者之间没有差异。

病例对照研究包含26位感染COVID-19的风湿性和肌肉骨骼疾病患者和62位感染COVID-19的非风湿性和肌肉骨骼疾病患者对照。在病例和对照之间的入院前COVID-19症状持续时间、住院时间或当地胸部X射线评分系统上无显著差异。累及肺部出现重度呼吸道表现的26例患者中有17例(65%)采用糖皮质激素治疗,6例使用tocilizumab(托珠单抗)治疗;这26例患者中发生了4例(15%)血栓形成事件。这26例患者有4例(15%)患者死亡,26位对照患者中死亡6例(10%)。

在风湿性和肌肉骨骼疾病患者人群中,COVID-19的感染率较高,COVID-19的感染的不良预后与患者年龄大、有并发症相关,但与风湿病的类型或免疫抑制剂的应用程度无关。

原始出处:

Micaela Fredi,et al. COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study. The Lancet Rheumatology. June 18, 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1830701, encodeId=08f81830e01da, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jan 08 04:47:02 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881284, encodeId=341c881284c4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e37b1737491, createdName=1df00607m15(暂无匿称), createdTime=Mon Aug 31 09:49:01 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457524, encodeId=9fbe145e524b6, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Sun Jun 21 08:47:02 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028206, encodeId=8e48102820615, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Fri Jun 19 20:47:02 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033845, encodeId=a99f103384583, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Fri Jun 19 20:47:02 CST 2020, time=2020-06-19, status=1, ipAttribution=)]
    2021-01-08 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1830701, encodeId=08f81830e01da, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jan 08 04:47:02 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881284, encodeId=341c881284c4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e37b1737491, createdName=1df00607m15(暂无匿称), createdTime=Mon Aug 31 09:49:01 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457524, encodeId=9fbe145e524b6, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Sun Jun 21 08:47:02 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028206, encodeId=8e48102820615, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Fri Jun 19 20:47:02 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033845, encodeId=a99f103384583, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Fri Jun 19 20:47:02 CST 2020, time=2020-06-19, status=1, ipAttribution=)]
    2020-08-31 1df00607m15(暂无匿称)

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1830701, encodeId=08f81830e01da, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jan 08 04:47:02 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881284, encodeId=341c881284c4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e37b1737491, createdName=1df00607m15(暂无匿称), createdTime=Mon Aug 31 09:49:01 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457524, encodeId=9fbe145e524b6, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Sun Jun 21 08:47:02 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028206, encodeId=8e48102820615, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Fri Jun 19 20:47:02 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033845, encodeId=a99f103384583, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Fri Jun 19 20:47:02 CST 2020, time=2020-06-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1830701, encodeId=08f81830e01da, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jan 08 04:47:02 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881284, encodeId=341c881284c4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e37b1737491, createdName=1df00607m15(暂无匿称), createdTime=Mon Aug 31 09:49:01 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457524, encodeId=9fbe145e524b6, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Sun Jun 21 08:47:02 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028206, encodeId=8e48102820615, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Fri Jun 19 20:47:02 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033845, encodeId=a99f103384583, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Fri Jun 19 20:47:02 CST 2020, time=2020-06-19, status=1, ipAttribution=)]
    2020-06-19 公卫新人

    新冠肺炎,疫情何时才能消失

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1830701, encodeId=08f81830e01da, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jan 08 04:47:02 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881284, encodeId=341c881284c4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e37b1737491, createdName=1df00607m15(暂无匿称), createdTime=Mon Aug 31 09:49:01 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457524, encodeId=9fbe145e524b6, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Sun Jun 21 08:47:02 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028206, encodeId=8e48102820615, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Fri Jun 19 20:47:02 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033845, encodeId=a99f103384583, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Fri Jun 19 20:47:02 CST 2020, time=2020-06-19, status=1, ipAttribution=)]
    2020-06-19 goodbing

    顶刊就是不一样,质量很高,内容精彩!学到很多

    0

相关资讯

Ann Rheum Dis:风湿病患者感染新冠病毒的临床特征和预后

感染COVID-19的风湿病患者更可能需要机械通气,但其临床特征和住院率与非风湿病患者相似。

Semin Arthritis Rheu:tDMARDs治疗的风湿病患者COVID-19的发病率

与普通人群相比,使用tDMARDs治疗的成人和儿童风湿病患者出现COVID-19感染或更严重疾病结局的风险并未升高。

Ann Rheum Dis:慢性炎性和自身免疫性风湿病患者COVID-19的患病率

AI/IMID患者被医院诊断为COVID-19的风险不同。年龄、治疗和疾病特异性因素的相互作用对患病风险有影响。

Ann Rheum Dis:风湿病患者中与COVID-19住院相关的特征

研究发现风湿病患者中,糖皮质激素≥10mg/天与住院几率升高相关,而抗TNF与住院几率下降相关。

Ann Rheum Dis:武汉风湿病患者感染COVID-19的临床特征

在感染COVID-19的风湿病患者中,呼吸衰竭更为常见。

Arthritis Rheumatol:靶向免疫抑制剂治疗的风湿病患者中COVID-19的发病率

ts/bDMARDs治疗的患者COVID-19发病率和严重程度与同一地区的普通人群没有显著差异。